AbbVie Inc.

Margin of Insight’s primer argues AbbVie has delivered the most successful post-Humira patent transition in biopharma, with Skyrizi and Rinvoq already surpassing peak Humira sales and management guiding 2026 revenue to about $67 billion and adjusted EPS to roughly $14.4–14.6. It highlights a 14x forward P/E, a roughly 3.2% dividend yield and sell-side targets in the $230–$250 range as the core upside drivers, while flagging eventual Skyrizi/Rinvoq loss of exclusivity, Medicare IRA pricing on Imbruvica, aesthetics softness and elevated debt as key long-term risks.

Ultra Stock Analysis Pro assigns a buy rating on AbbVie with an average analyst target of about $249 per share, implying roughly 21% upside from the report’s $206.60 reference price, and bases its constructive view on a 55.6% backtested win rate, +40.8% total return, a 12.8x forward P/E, double‑digit revenue growth and high (≈76.5%) institutional ownership. It complements this thesis with detailed technical metrics, news-sentiment analysis and a comprehensive risk framework around earnings volatility, trend strength and ATR-based stop-loss positioning, while still recommending a hold stance pending stronger technical “confluence” signals.

Balfour Capital Group’s research note presents AbbVie as a diversified immunology-led biopharmaceutical company with Q3 2025 revenue of about $14.6 billion and an outlook for mid‑ to high‑single‑digit EPS growth through 2026–2027, driven by Skyrizi, Rinvoq, recovering aesthetics and stable neuroscience and oncology contributions. It emphasizes strong institutional ownership (≈72%), consensus buy recommendations with average price targets around $190–$210 and the expectation that Skyrizi and Rinvoq will exceed Humira’s peak by 2027, while acknowledging ongoing Humira biosimilar headwinds and typical large-cap pharma risks such as regulatory changes and pipeline execution.

DBS maintains a hold rating on AbbVie with a 12‑month target price of $208, derived from about 15.4x 2025 forecast EPS, framing the stock as fairly valued after a successful shift from Humira toward high-growth immunology assets Skyrizi and Rinvoq and a rapidly expanding neuroscience franchise that together are driving double‑digit revenue and EPS growth. The report highlights robust free cash flow, disciplined SG&A and R&D spending and strong margins as positives, but balances them against tariff exposure (including a 15% US–EU pharma duty), biosimilar erosion in oncology, macro-sensitive aesthetics demand and near‑term margin dilution from heavy late‑stage pipeline investment, leading to a broadly balanced risk–reward profile.